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 Biotechnology is the utilization of biological organisms, processes, and systems for the 
generation of useful products. A significant component of the biotechnology industry is 
comprised of pharmaceutical companies that make and market therapeutic drugs.  In recent years 
pharmaceutical companies have shifted significantly from the creation of chemically synthesized 
small molecule drugs to new biologic drugs produced in living hosts. In 2009, intellectual 
property law firm Withers & Rogers released a report showing that patent filings for biologics 
accounted for 60% of the total patent filings from the top 10 pharmaceutical companies.
1
 
Additionally, the biopharma industry consultancy group KMR released a report showing that 
25% of biologics in Phase II reached the market compared to 10% of small molecules between 
2006 and 2010.
2
 Amongst this classification of biologics are antibody drugs which hold a market 
share of more than 10 billion dollars.
3
   
Because of their interaction with immune effector cells, antibodies have a plethora of 
current and potential uses. In terms of therapeutic application, antibodies can be used to treat 
viruses, autoimmune diseases, and even various cancers. Utilization of the human body’s own 
immune cells is a major advantage for antibody-based therapeutics. The potential advantages and 
diverse applications of antibody based drugs have contributed to the pharmaceutical shift 
towards biologics. 
1.1 Antibody structure 
The basic structure of an antibody is comprised of two 
identical heavy chains and two identical light chains assembled 
as a tetramer similar in shape to the letter Y, as shown in figure 
1. Each heavy chain has four protein domains with interchain 
Figure 1. Basic antibody structure  (IgG1) 





Figure 2. Antibody agglutination. Antigen binding sites on each 
antibody pair up with surface antigens present on microbes.
3 
disulfide linkages in the hinge region. Light chains have two domains which are often disulfide 
linked to the CH1 domain of the heavy chain. The antigen binding sites are located at the 
intersection tip between the light chain and the heavy chain. Binding specificity is determined by 
regions of high variability termed complementary determining regions (CDRs). Genetic 
recombination and error prone mechanisms within the bone marrow can produce up to 10
11
 
unique variable region combinations.
4
 Finally, the Fc domain is the heavy chain protrusion at the 
bottom. The Fc domain is responsible for binding to Fc receptors on the innate effector cells. 
Antibody-antigen binding facilitated by protein variable regions stimulates an immune response 
which is mediated by the binding between Fc domains and immune effector cells.  
1.2 The immune response 
Rather than grouping together in a one-to-one pair, multiple antibodies bind to multiple 
antigens in a higher level complex. This process is known as agglutination (Figure 2). The 
formation of this complex helps facilitate efficient ADCC, or antibody-dependent cell mediated 
cytotoxicity, by assembling microbes together to increase effector cell accessibility. Multiple 
interactions between antibody and antigen introduce an avidity effect resulting in strong 
attachment. When antibody-antigen binding is significantly high, the antibody Fc domains cross 
link receptors on effector cell surfaces to overcome the threshold required for activation. 
Methods of antigen destruction vary from phagocytosis via macrophages or neutrophils to 
perforin and granzyme mediated induction of apoptosis via 
natural killer cells.
5
 Antibody function is mediated 
through differential binding patterns to various Fc 
receptors. IgG acts through Fc gamma receptors and 





Figure 3. FcγR expression patterns. Green=Activating, Red=Inhibiting. 
 
1.3 Antibody classes and their receptors  
Five different classes of antibodies are naturally synthesized by the human body. Of these, IgG 
and IgA have the highest concentration in human serum and have shown therapeutic potential.
6
 
1.3.1 IgG and Fcγ Receptors 
The most abundant class in serum is immunoglobulin G (IgG). IgG contains two variable 
binding domains and one effector cell binding domain (Fc domain). All FDA approved antibody 
drugs thus far have been made with an IgG1 backbone as this isotype has the highest binding to 
certain important inflammatory receptors.
7
  
The Fc gamma receptor class is made up of five receptors: FcγRI (CD64), FcγRIIA 
(CD32), FcγRIIB (CD32), FcγRIIIA (CD16a), and FcγRIIIB (CD16b). Expression profiles of 
each Fcγ receptor are shown in Figure 3.8 FcγRI has been shown to mediate ADCC and 
participate in endocytosis leading to phagocytotic function of effector cells.
9
 FcγRIIA is a 
commonly regarded killing receptor that is known to stimulate phagocytosis and neutrophil 
degranulation.
10,11
 FcγRIIB, on the other hand, is the only Fc gamma receptor that has an 
inhibitory function. When a pathogen-bound IgG binds to FcγRIIB, granted the activation 
threshold is reached, the cytotoxic process comes to a halt. Activating FcγRs in the proximity of 
bound FcγRIIB are also adversely 
affected.
12
 Finally, FcγRIIIA is an 
activating receptor that is known to 
facilitate phagocytosis, induce ADCC 
through natural killer cells, and stimulate 







1.3.2 IgA and FcαRI 
Immunoglobulin class A (IgA) is the most common type of antibody in the mucosa and 
the second most abundant in the serum. IgA antibodies are represented in higher serum 
concentrations in humans than in the sera of other animal species. In serum, IgA is 
predominantly monomeric. However IgA present in secretions, i.e. bile, saliva, nonvascular 
fluids, is usually dimeric. Human IgA can be further divided in to two different subclasses: IgA1 
and IgA2. The structural difference between these subclasses is the absence of a thirteen-amino 
acid sequence in the hinge region of IgA2.
15
 Understanding the interaction between IgA and its 
Fc receptor is important for recognizing the role that an IgA/IgG hybrid antibody would play as a 
therapeutic. 
Most of the investigated IgA therapeutic effects are generated through interaction with 
FcαR1 (CD89). This Fc receptor is expressed on cells of the myeloid lineage including 
macrophages and neutrophils. Human FcαRI binds to a region of IgA between the CH2 and CH3 
domains in the Fc. The IgA-FcαRI complex activates a variety of antigen killing reactions such 
as respiratory burst, phagocytosis, and cytokine production. Unfortunately, the circulation half-
life of IgA is significantly less than that of IgG at 5.9 days for serum IgA1 and 4.5 days for 
serum IgA2 (IgG can last up to 23 days depending on isotype).
16
 Despite this drawback, IgA has 
therapeutic potential due to its strong interaction with immune effector cells, specifically 
neutrophils, the most common form of white blood cell in mammals.
6
 
Neutrophils form an essential part of the innate immune system by responding quickly to 
sites of inflammation. These cells are phagocytes that are able to ingest and destroy targets that 
are coated with opsonins, or molecules that present bound antigens. As part of the cell killing 





peptides to cause target destruction (Figure 4). Most of these proteins are stored in granules 
which are released in a process called degranulation.
17
  
1.3.3 IgA vs. IgG 
The advantages of using IgA as a therapeutic over IgG are related directly to neutrophil 
recruitment and activation. It has been demonstrated that FcαRI is the most potent neutrophil Fc 
receptor to induce antibody-dependent tumor cell killing.
18
 In fact, in a side by side comparison, 
the degree of neutrophil-initiated colon carcinoma cell killing was higher in the presence of IgA1 
mAbs compared to an IgG1 counterpart.
19
 Additionally, IgA does not bind FcγRIIb, the gamma 
class inhibitory receptor. Since FcαRI is the only Fcα receptor, no inhibitory receptor analog 
exists for the α class. Its ability to potentiate the effect of inflammatory neutrophils through 
CD89 and its circumvention of inhibitory receptor binding makes IgA a powerful potential 
therapeutic. However, this potential for potency can only be realized through the precise design 
and engineering of antibody mutants. 
1.4 Antibody Engineering 
More often than not, protein therapeutics are made from antibodies. Antibody variable 
regions are often discovered through a rational trial and error process that involves the injection 
of a specific antigen into a mouse. The murine immune system will detect the foreign material 





and create a pool of polyclonal antibodies against it. Recently, Sanofi and partner Regeneron 
have engineered mice that have fully human immune repertoires that can produce entirely human 
antibodies.
20
 These antibodies can be expressed and selected for certain binding characteristics 
using hybridoma cell lines, or B lymphocytes fused with immortalized myeloma cell lines.
21
 
Proliferating B cells generated from the same lineage can produce monoclonal antibodies. 
Monoclonal antibodies (mAbs) are used therapeutically because every clone binds to the target 
antigen in the same manner; in contrast, the heterogeneity of polyclonal antibodies can be risky 
for a patient. With the development of modern cloning techniques, researchers are now able to 
isolate B cells and clone select sequences in to expression vectors that can be screened using 
techniques such as phage display or periplasmic expression.
22,23
 In particular, engineering a 
hybrid antibody consisting of two different classes requires specific modifications of the Fc 
domain. 
There are two predominate methods for engineering better therapeutic antibodies: 
variable domain manipulation and Fc manipulation. The variable domain of an antibody targets 
the antigen while the Fc domain binds to receptors on various immune cells to affect potent 
cellular responses. Increasing binding efficacy between Fc domain and Fc receptor can augment 
drug potency. In the treatment of cancers, high avidity antibody-antigen complexes ligate several 
Fc receptors together on a responding immune cell to initiate intracellular signaling pathways 
that ultimately trigger the release of cytotoxic components and cause the destruction of the tumor 
cell. By improving the binding to the Fc receptor, one can recruit more receptors and potentially 
generate stronger immune responses. Moreover, since toxicity is almost entirely dependent on 
drug dose concentration, a more effective drug that requires lower dosage is safer for the patient. 





2. Creation of an IgA/IgG Hybrid Antibody 
The ability to bind two different classes of Fc receptors is a desirable trait for an antibody based 
therapeutic. The IgG and IgA classes are the first and second most prevalent antibody isotypes in 
the human body.
24
 Most antibody drugs use IgG as a backbone because it is the most effective 
agent of ADCC due to its natural prevalence.
25
 However, combining regions from different 
classes to yield an antibody with dual binding has significant potential. IgA was the selected as 
the desired second class because of the potency of the FcαRI receptor. Its high expression on the 
surface of neutrophils makes FcαRI a powerful Fc receptor for the purposes of antibody based 
tumor cell killing. 
2.1 Previous Hybrid Fc Engineering Work 
Previous work from other labs on the creation of hybrid IgG/A focused on the 
substitution of entire heavy chain constant domains and the fusion of additional protein domains 
to IgG to investigate FcαRI binding. The first hybrid protein was a domain swap variant in which 
the entire IgG CH3 (constant region 3 of the heavy chain) was replaced with the IgA CH3 
analog. However, this variant was found to have no binding to FcαRI.
26
 More recently, a hybrid 
variant was constructed by attaching the IgA CH3 domain to the C-terminus of the IgG heavy 
chain.
27
 The new variant was able to retain FcγRI binding and could dimerize via J-chain linking 
of the IgA CH3 peptide appendages. However, the variant showed lower serum persistence due 
to the higher avidity interactions with FcRn. FcRn is an Fc receptor responsible for the recycling 
of immunoglobulin to prevent lysosomal degradation. Antibodies bind to FcRn and are recycled 
to the cell surface.
28
 The extra heavy chain domain in the γγγα variant increased the avidity 
interactions with FcRn which prevented endosomal release on the cell surface. Lower half-life 







These past experiments with hybrid variants show the potential for IgG/A hybrid antibodies but 
also reveal the problems that must be overcome in the protein engineering process. 
2.2 Project Rationale 
 Engaging both FcγRI and FcαRI using bispecific antibody fusions for in vitro cell killing 
has been successful in the past. An ADCC assay was done in the presence of two antibody 
fusions, one that bound a surface antigen as well as FcγRI and a second that bound the same 
surface antigen as well as FcαRI. Together, this combination destroyed tumor cells to a higher 
degree than either antibody alone.
24
 However, injecting a patient with two different types of 
antibodies is not ideal. First, matching glycan heterogeneity profiles for two different antibodies 
in a single drug would be very time consuming and expensive. The FDA would be hesitant to 
approve a drug with such high batch to batch inconsistency. Second, this potential drug would 
bind to the inhibitory FcγRIIb receptor thereby decreasing potency. Our approach builds on this 
finding and avoids these safety problems by making one single antibody backbone. Furthermore, 
cancer patients in particular are often immunocomprimised; thus, there is a pressing need for 
treatments that recruit more abundant immune cell populations. FcαRI is highly expressed on 
neutrophils which are well represented in serum (~70% of all effector cells). Our goal is to create 
a variant that can use these cells to induce the desired immune response 
 To achieve hybrid binding, we decided to adopt an approach that incorporates the domain 
swap ideology with other rational design techniques. First, we examined the crystal structure of 
the IgA-FcαRI complex using protein modeling software called PyMOL. Different residues were 
tested for binding importance through a process called alanine scanning. We isolated a ‘protein 
loop’ of the CH2 region of IgA that seemed to be very important for binding to FcαRI. 





hotspots. However, changing residues haphazardly can result in undesired changes in tertiary and 
quaternary structure. As a result, the protein may have trouble folding and may not express well 
in bacterial or mammalian cells. To circumvent this issue, we decided to graft the entire CH3 
domain from IgA in to IgG. Our hope was that inserting an entire domain from a protein that is 
known to fold and express well rather than changing individual residues would result in higher 
binding retention. Also, substituting large domains would preserve recognizable amino acid 
sequences and could result in lower immunogenicity. The upstream CH2 binding loop from IgA 
was also included in our first round of mutant designs. Our plan was to make three mutants using 














3. Engineering Methods 
3.1 IgA/G Variant Design 
 Four different combinations of the IgA CH3 domain and IgA CH2 binding loop were 
grafted in to IgG. Specifically, mutant A replaces IgG1 residues 245-258 (KGQPR….LSPGK) 
with IgA residues 251-263 (PALEDLLLGSEAN) including an additional glycine after IgA 
residue. Mutant B exchanges IgG1 residues 340-447 (KGQPR….LSPGK) with IgA1 residues 
340-450 (SGNTF…KTIDR). Mutant C replaces IgG1 residues 340-447 (KGQPR….LSPGK) 
and residues 245-258 (PKPKDTLMISRTPE) with IgA1 residues 340-450 (SGNTF…KTIDR) 
and 251-263 (PALEDLLLGSEAN) respectively. Similarly, mutant D includes the two swaps 
from mutant C but also adds a glycine after IgA residue 263 (after the CH2 binding loop). The 
additional glycine in mutants A and D was added to match the loop length of IgG and also to add 
flexibility for folding. Figure 5 shows the four initial binding mutants. (Note: Mutant A was 
constructed after characterization of Mutants B,C,D). 
  
3.2 Construction and Expression of IgA/G Variants 
 Mutants A-D were made via overlap extension PCR and cloned into the vector pMaz-
FcγRI-His. The dpnI digested product was then transformed in to JUDE-1 electrocompetent 






flasks. Plasmid DNA was prepared by miniprep (Qiagen) for transfection. 293Fectin 
Transfection Reagent (Invitrogen) was used to transfect HEK293F (Invitrogen) cells cultured in 
GIBCO FreeStyle™ 293 Expression Medium (Invitrogen) in accordance with the manufacturer’s 
instructions. 5-6 days after transfection the cell suspension was centrifuged at 2000 rpm for 10 
mins to recover the supernatant fraction. The protein supernatant was then purified using an Ni-
NTA purification system to isolate the proteins via His-tag affinity. 25x PBS was added to the 
protein supernatant to a final concentration of 1x in addition to 10mM imidazole. The solution 
was passed through Ni-NTA affinity columns for protein binding. Bound protein was washed 
with 20 mM imidazole in PBS and eluted with 250 mM imidazole in PBS directly into Amicon 
10kDA spin columns for buffer exchange and concentration.  
3.3 ELISA Testing 
Ni-NTA ELISA plates (Qiagen) were coated with 4ug/mL of each of the mutant Fc 
domains (Sino Biological) in 1x PBS containing 0.05% Tween (PBST) and washed three times 
in PBST at pH 7.4. To the first well 66.66 uL of 10 ug/mL of each of the test Fc receptors 
(FcαRI-GST, FcγRI-GST, FcγRIIa-R131-GST, FcγRIIb-GST or FcγRIIIa-F158-GST) dissolved 
in PBS with 2% milk (PBSM) was added followed by a 1:4 serial dilution down the plate. After 
1 hour of incubation at room temperature, the plates were washed and 50 uL PBSM with goat 
anti-GST HRP (GE Healthcare) 1:5000 was added. Following 1 hour incubation, the plates were 
washed 3x with PBST and developed with 50 uL TMB substrate per well (Thermo Scientific). 
To neutralize, 50 uL of 1 M H2SO4 was added per well and the absorbance at 450 nm was 






3.4 Alanine Mutagenesis 
Based on crystal structure data and Rosetta modeling, 11 sites in the IgA Fc domain that 
were identified or suspected to interact with FcαRI were selected for alanine scanning (Figure 6). 
Eleven Fc mutants, each with a single alanine substitution, were made using overlap extension 
PCR. After the mutants were cloned and purified, ELISA analysis was performed to compare the 
binding to wild type (WT) IgA. Costar 3590 96-well plates were coated with our 11 mutants. 
Next, FcαRI-GST was added at 20 μg/ml and binding was detected with anti-GST HRP. Binding 
efficacy was compared to IgA and IgG as positive and negative controls, respectively. 
Additionally, 2 µg of each mutant protein was loaded in to a 4-20% SDS-Agarose Protein Gel 
(Invitrogen) and run at 110 W for 30 mins.  
3.5 Surface Plasmon Resonance (SPR) Analysis 
Surface plasmon resonance analysis was carried out using a BIAcore 3000 instrument to 
determine binding kinetics (GE Healthcare). Five nanomoles of the mutant of interest (mutant D) 
and the two controls were immobilized on CM5 sensor chips by amine coupling as 
recommended by the manufacturer. The dissociation experiments were performed in HBS-EP 
buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA, and 0.005% P20 surfactant) (GE 
Healthcare). Dimeric forms of FcαRI-GST, FcγRIIb-GST, FcγRIIa(H)-GST, and monomeric 
FcγRI were injected in duplicate at a rate of 30 µl/min for 60 seconds. A dissociation time of 5 
minutes was set to examine the protein-ligand binding kinetics. After each injection, the chip was 
regenerated to remove both the ligand and the analyte for further machine runs. For the dimeric 
receptors, the chip was regenerated by sequential injection of 50 mM glycine (pH 4.0), 50 mM 
glycine (pH 9.5), and 3 M NaCl for 2 min. each. For the monomeric FcγRI receptor, the chip was 





constants (KD) for monovalent receptor binding were calculated by fitting a 2:1 bivalent analyte 
model to the data using BIA evaluation 3.2 software (GE Healthcare).  
3.6 ADCC Assay: Cytotoxicity of SKBR3 Tumor Cells 
Fresh blood was drawn and diluted 1:1 with PBS containing 2% FBS. Lymphoprep 
(Sterncell Technologies) was added 1:2 to blood solution before centrifuging at 800 g for 20 
mins. Serum, mononucleated cells, and lymphoprep were discarded and diluted BD Pharm Lyse 
10x Buffer was added to RBC solution 1:10. After 15 min incubation, solution was centrifuged 
at 200 g for 5 minutes, decanted and washed in PBS with 1% FBS, and spun again at 200 g for 5 
minutes. Pellet was resuspended in PBS with 2% FBS to a concentration of 5*10
7 
cells/ml. Fifty 
µL of Neutrophil enrichment cocktail (Stemcell Technologies), 100 µL magnetic nanoparticles 
and PBS 2% FBS were added to the suspension for a final volume of 5 mL. Neutrophils were 
isolated using a high power magnet from EasySep’s Human Neutrophil Enrichment Kit. Cells 
were cultured in complete RPMI medium in the presence of 10 ng/mL G-SCF (PeproTech) and 
50 ng/ml recombinant human IFN-γ (PeproTech) overnight. Antibodies were prepared at 40 
ug/ml. Max lysis buffer was made from Triton X-100 at 2% v/v, SDS 1% w/v, 100 mM NaCl, 
and 1mM EDTA-2Na. In parallel, SkBR3 (Her2+ MDA-MB-453) cells were grown in McCoy’s 
5a complete media. Cells were passaged every 2-3 days until harvesting via Trypsin-EDTA. 
Pelleted cells were washed with PBS and resuspended in 1 ml ADCC culture media (RPMI 1640 
with 10% ultralow IgG serum). Cells were labeled for 1 hr with Na51Cr04 (PerkinElmer Life 
Sciences). Labeled cells were washed in ADCC culture media and resuspended at desired 
concentration. Fifty µL tumor cells, 50 µL antibody solution at 20 µg/ml, 2 µg/ml, and 0.2 µg/ml 
concentrations, and 100 µL neutrophils were added to each desired well of U-bottom tissue 
culture plate. Effector cells and target cells were cocultured in complete media in an E:T ratio of 





2000 rpm for 10 mins and aliquots of supernatant were analyzed for chromium-51 levels in a 






4. Results and Discussion  
4.1 Alanine Mutagenesis 
Eleven different mutants were made with a single alanine substitution in each. Figure 6 
below shows IgA (gray) in a binding complex with FcαRI (orange). Since wild type IgA has a 
homodimeric heavy chain structure, there are two binding interfaces present. Residues were 
selected for their proximity to the FcαRI amino acid chain Additionally, modeling with Rosetta 
software was used to resolve unclear parts of the crystal structure to help with residue selection 
(selected residues shown in Figure 6).  
After selecting the residues, the mutants were cloned, expressed, and purified. Single 
amino acid substitutions often change protein expression, and assembly in addition to binding 
Figure 6:  IgA residues selected for alanine substitution 





efficacy. Thus, two micrograms of each purified mutant protein was loaded in to a 4-20% 
polyacrylamide gel. The protein comprising each mutant was separated by molecular weight via 
gel electrophoresis (Figure 7). 
The scale on left is in units of kilodaltons (kDa). An average IgA Fc domain has a 
molecular weight of about 25.2 kDa. A dimerized IgA Fc domain would have a molecular 
weight of 50.4 kDa. The brightest band for each lane should be around the 50 kDa mark. 
However, due to the addition of carbohydrate chains (glycosylation) some of the protein appears 
at a higher molecular weight. The heterogeneous mixture of added glycans slows down protein 
migration through the gel and account for the diffuse bands. Ten of the mutants show protein at 
the correct molecular weight with the exception of mutant L258A. Lack of displayed protein 
near the 50 kDa mark signifies the importance of this residue for assembly of the Fc dimer.  
Finally, an ELISA was run to compare the relative binding affinities of all eleven mutants 
to FcαRI.  IgA and IgG were included in the assay as a positive and negative control, 
respectively. Figure 8 shows the mutant binding affinities normalized to IgA. Significant binding 
residues display low affinity relative to wild type IgA because the alanine mutation changes 
binding capacity. The colored dots represent residue importance: green for low, orange for 
medium, and red for high. The question mark over L258A signifies the lack of correct protein 





expression due to mutation of the 258
th
 residue. These data show that the two residues marked 
with red dots, 313 and 433, are the most influential residues for binding to FcαRI. Since residue 
433 is located in the IgA CH3 domain, we chose to insert this entire domain in to IgG. 
4.2 Initial Mutant Binding Characterization 
Mutants B, C, and D were constructed according to the schematic shown in Figure 1. 
Multiple ELISAs were performed to fully characterize our mutants with respect to an array of Fc 
receptors. These antibodies were made by substituting domains from IgA in to a backbone of 
IgG. The goal was to engineer an antibody that retains native IgG binding to the FcγRs but also 
has de novo binding to FcαRI, a receptor characteristic of IgA. Preliminary ELISA results are 
shown in figures 4 and 6 below. 
Out of the three mutants, Mutants C and D showed the highest binding to FcαRI.  Figure 
9 shows the absorbance curve of the ELISA against an increasing dilution factor. Mutant D was 
chosen over Mutant C due to the SDS-PAGE protein expression gel shown in Figure 10. The 
single band of protein in lane D demonstrates better assembly of the mutant most likely due to 
the additional glycine residue. While mutant D did not show binding comparable to wild type 
IgA there is substantially higher binding than IgG, our negative control. More accurate 
quantification of binding affinity was further evaluated by SPR techniques.  
Figure 9: Mutant binding efficacy to FcαRI. Mutants C and D show highest 
levels of binding compared to IgA wild type. 
Figure 10: SDS-PAGE analysis of mutant Fc 






Mutants B, C, and D all showed similar binding to FcγRI (Figure 11). As expected, our positive 
control of wild type IgG showed the most binding to FcγRI. Our engineered mutants appeared to 
have about half the level of FcγRI binding as our positive control. The negative control, wild 
type IgA, showed almost zero binding to FcγRI. These data indicate at least some retention of 
binding to the Fc gamma receptor class.  
Due to the therapeutic importance of the Fcy receptors, ELISAs were run on the rest of 
the gamma receptor class to determine our mutants’ binding efficacy. Our engineered mutants, in 
comparison to IgG, had significantly higher binding to FcγRIIA. And, perhaps more importantly, 
mutants B, C, and D all had very low binding to FcγRIIB. High binding efficacy to IIA and low 
binding efficacy to IIB is desired for effective antibody based therapeutics. A summary of our 
Table 1: Summary of binding efficacies to important Fc receptors. Quantity of dots symbolize level of binding. 
Figure 11: Mutant binding efficacy to FcγRI. Mutants B, C, and D all 





ELISA data is displayed in Table 1. These results show that our engineered mutants have at least 
some of the desired characteristics of wildtype IgG and IgA antibodies. However binding to 
FcγRIIIA was almost non-existent. Any small perturbation in the CH2/CH3 domain structure 
seemed to negatively affect FcγRIIIa binding. To further explore FcγRIIIa sensitivity, Mutant A 
was designed and tested for CD16a efficacy. 
4.3 Mutant A characterization 
Mutant A only contains the CH2 binding loop and the additional glycine flexor without 
any CH3 residues from IgA. In contrast, Mutants B-D all contained domain swaps of the CH3 
domain and also almost completely lost binding to FcγRIIIa. Mutant A was designed to test 
whether the CH3 swap was the main cause of CD16a binding loss. Results from the ELISA are 
shown in Figure 12. Mutant A and Mutant D show negligible binding to CD16a compared to the 
IgG positive control. FcγRIIIA binding must be very sensitive to conformational changes in the 
CH2 or CH3 domain. It is possible that IgG native residues in the CH2 binding loop and CH3 
domain are necessary for CD16a binding. These data show that even small changes in the IgG 
CH2 domain will disrupt CD16a binding highlighting the difficulty of retaining binding to this 
receptor in the construction of a hybrid antibody. 

































Figure 12: Binding efficacy to FcγRIIIA. Mut A and Mut D have significantly lower binding than 





4.4 The Importance of IgA Glycosylation 
 
In eukaryotic and prokaryotic cells, ribosomes are responsible for translating mRNA 
strands in to amino acid chains. Select proteins are modified further by the endoplasmic 
reticulum and golgi apparatus. These organelles often add carbohydrate chains, or glycans, to 
chosen functional groups of the protein. This type of post-translational modification known as 
glycosylation influences protein structure and function.  
Producing consistent antibody glycosylation profiles among different expression batches 
is often very difficult. If a specific glycosylation pattern is needed to obtain correct antibody 
functionality, this antibody-based drug would be more expensive to produce and may not clear 
the FDA. In this experiment we analyzed the the importance of human IgA glycosylation to 
determine the extent of glycan matching that would be needed to commercialize our mutants. 
First, we expressed IgA in bacterial cells. The E. Coli used cannot glycosylate and as a result 
expressed IgA without any additional glycan attachments. Figure 12 indicates the assembly of 
IgA Fc in bacteria was not perfect due to the presence of a monomeric Fc fraction. Regardless, 
non-glycosylate3 IgA Fc was compared to glycosylated IgA Fc isolated from human serum by 
ELISA. IgA in human serum is primarily monomeric (about 85-90%) with a minor percentage in 
polymeric form.
29









Figure 13: SDS-PAGE of purified IgA Fc 
expressed in bacteria 
Figure 14: Relative binding of Serum IgA Fc 
and Bacterial IgA Fc to FcαRI. Black dots 





glycosylation and dimerization discrepancies, levels of FcαRI binding to human IgA Fcs and IgA 
Fcs expressed in bacteria were similar (Figure 14). From this experiment we concluded that 
glycosylation of IgA Fc is not critical for FcαRI binding. These results indicate that 
glycosylation and assembly differences between our HEK293 expression system and the natural 
human protein expression system are negligible. As a result, we can express aglycosylated IgA-
derived mutants in bacteria without suffering a significant decrease from WT binding.  
4.5 Surface Plasmon Resonance (Biacore) 
Surface plasmon resonance tests using a Biacore 3000 machine were performed to verify 
ELISA results. This technique is used to examine the equilibrium dissociation constants between 
a protein (ligand) and its analyte, in this case between an Fc domain and its Fc receptor. Wild 
type IgA was used as a positive control and bovine serum albumin (BSA) was used to subtract 
non-specific receptor binding (negative control). Biacore tests are more robust and more 
quantitative than the simple ELISA tests described above. Binding between Mutant D and 
FcαRI, FcγRI, FcγRIIa, and FcγRIIb was examined to fully characterize our antibody mutant. 
Figure 15: Biacore (SPR) curve fit for IgA complexed with FcαRI. Smooth association and gradual dissociation indicates high levels of binding. 





Curves returned by Biacore injections consist of refractive index values over time. The gradual 
increase in refractive index represents antibody-Fc receptor binding while the gradual decrease 
represents antibody-Fc receptor dissociation. These curves were fit to a monovalent Langmuir or 
bivalent analyte model to obtain association (ka) and dissociation (kd) constants. The Biacore 
curves for IgA complexed with FcαRI and Mutant D complexed with FcαRI are shown in figures 
15 and 16, respectively.  
A summary of the dissociation constant data obtained via SPR analysis is shown in Table 
2. The dissociation constants are listed in the first column under each Fc receptor heading. The 
second column displays the chi-squared (χ
2
) values for the Langmuir or bivalent analyte curve 
fitting. Chi-squared values represent the goodness-of-fit of a regression method in which a lower 
Table 2: Comparison of Kd and χ
2
 values for IgA and Mutant D binding to different Fc receptors.  
 Figure 16: Biacore (SPR) curve for Mutant D complexed with FcαRI. Sharp increase and distinct drop-off indicates lower levels of binding. 







 indicates a more exact fit. The χ
2
  value for Mutant D binding to FcαRI is about double the χ
2
 
value for IgA binding to FcαRI. These data indicate that our engineered mutant D displays 
slightly more than half the original IgA binding to FcαRI binding. Chi-squared values for Mutant 
D binding to Fcγ receptors were compared to known IgG-Fcγ χ
2
 values. It is important to note 
that we have low confidence about the Kd
 
value for FcγRIIa due to the high χ
2 
value.   
A binding comparison between Mutant D and wild-type IgA/IgG is shown in Figure 17. 
Mutant D showed about 55% of de novo FcαRI binding while retaining about 75% of FcγRI and 
FcγRIIa binding. Surprisingly, mutant D also displayed very low levels of FcγRIIb binding. 
Since RIIb is an inhibitory protein, minimizing interaction with this Fc receptor is expected to 
increase potency of ADCC or ADCP in the body.
30
 However, mutant D binding to FcγRIIIa is 
almost non-existent. Since FcγRIIIa is an important activating receptor, lack of Mutant D 













Figure 17: Binding comparison between mutant D and 
WT IgA/IgG. Gray bars indicate percentage of wild type 





4.6 ADCC Results 
An ADCC assay was designed to test tumor cell cytotoxicity. An overview of the 
experiment is shown in figure 18. Pure lysis buffer was used as a positive control to release the 
maximum amount of chromium 51 isotope into solution.  
Additionally, a well of mixed neutrophils and tumor cells without antibody was used as a 
negative control to measure background levels of antibody independent chromium release. Since 
human neutrophils naturally express FcαRI at higher levels than FcγRI, G-CSF and human IFN-γ 
were used to increase FcγRI expression by mimicking a state of immune activation during 
overnight culture.
31
 The results from the ADCC experiment are summarized in Figure 19. IgG 
Figure 18: Overview of chromium-51 release assay to measure 





displayed surprisingly low levels of tumor cytotoxicity, possibly due to ineffective activation of 
FcγRI. The neutrophils may need to be activated longer for higher FcγRI expression. IgA levels 
of cytotoxicity were significantly higher than those of IgG which is expected due to the high 
expression of CD89 on neutrophils.
32
 Mutant D showed higher cytotoxicity thanIgG but lower 
than IgA. Since mutant D binds to CD89 at slightly lower levels than IgA as shown from ELISA 
and SPR data, it is reasonable that mutant D is less cytotoxic than WT IgA. However, the data 
shows that partial activity through FcαRI makes mutant D more cytotoxic than IgG alone. Since 
IgG is the therapeutic standard for monoclonal antibody drugs, engineering an antibody with 
higher cytotoxic function than IgG is a significant step forward in the field of antibody 
immunotherapy.  
  
Figure 19: ADCC assay results showing relative levels of tumor cell killing 






The idea of treating cancer with antibody-based therapies dates back to the 1960s when 
antigen expression was examined using serological techniques.
33
 Since then, the field has 
evolved and only recently advanced to a stage necessary for drug creation. Since 1997, twelve 
antibodies have received approval by the FDA for treatment of solid tumor and blood-based 
malignancies.
34
 All 12 of these antibody drugs are made from the IgG isotype. Since IgG is the 
most common antibody class in human blood, no approved drug uses any other antibody isotype. 
However, exclusivity of an antibody class results in limitations of immune cell interactions. 
Engineering an Fc domain that interacts with more, unique Fc receptors can overcome this class 
limitation.  
IgA was chosen as a desired second class because of its interaction with FcαRI. This Fc 
receptor is expressed on cells of myeloid lineage including neutrophils. Since neutrophils are the 
most common type of white blood cell, their recruitment can lead to a formidable source of 
cytotoxic effector cells.
35
 Additionally, it has been demonstrated that FcαRI is the most effective 
neutrophil Fc receptor to induce antibody-dependent tumor cell killing, even more so than 
FcγRI.18 Creating an antibody that engages both FcαRI and Fcγ receptors could result in even 
more potent tumor cell killing through the action of different immune cells.  
After examining binding complexes on PyMOL and verifying residue importance 
through alanine scanning, we constructed four mutants that consisted of IgA domains grafted in 
to IgG. Instead of manipulating individual residues, we decided to swap large domains or loops 
to bolster expression, increase our chances of de novo binding, and decrease immunogenicity. 
Mutant D turned out to have the best combination of binding to FcαRI and protein expression. 
Quantification of Mutant D binding through SPR helped to fully characterize our antibody. 





FcγRI and FcγRIIa. Additionally, our engineered antibody does not bind very well to FcγRIIb 
(~12%) or FcγRIIIa ( ~2%). Retention of some Fcγ receptor binding along with new binding to 
FcαRI confirms our belief that hybrid binding is possible. 
Results from the SkBR3 ADCC assay verify that the introduction of new FcαRI receptor 
binding enhances tumor cell killing. Mutant D exhibits higher tumor cell cytotoxicity than IgG 
alone. The impact of this discovery could be very significant. As a platform for countless tumor 
specific variable domains, our engineered Fc could serve as an integral part of many future 
monoclonal antibody drugs. IgA may start to be used more as a therapeutic agent. In the future, 
hybrid Fc domains that engage many different immune cells may become commonplace in the 






6. Future Work 
In order to increase the impact of our discovery, a few more experiments must be run. 
First, we must examine FcγRI expression levels on neutrophils. IgG exhibited surprisingly low 
levels of cytotoxicity which may be a result of a lack of Fcγ receptors on the experimental 
neutrophils. Although G-CSF and IFN-γ were supposed to stimulate FcγRI expression on the 
neutrophil surface, the levels of FcγRI expression should be confirmed by FACS. The ADCC 
assay must then be repeated to verify our findings. 
A different cell-based assay must be performed to show that Mutant D has higher 
cytotoxicity than IgA in certain circumstances. In the presence of neutrophils, wild type IgA will 
most likely be preferred. However, in the presence of other immune cells that mostly express Fcγ 
receptors, mutant D may be preferred over IgA. Our results would have a higher impact if we 
should mutant D preference over WT IgA. In the future we may test the cytotoxicity of Mutant D 
in the presence of dendritic cells and/or full PBC fraction.  
After confirming the in vitro cytotoxicity of our antibody, we plan on testing our 
antibody in an immune compromised cancerous mouse. We will adoptively transfer human 
immune cells to the mouse along with our antibody to measure to measure in vivo effectiveness. 
Tumor cell count can be measured over time after the administration of our antibody. Comparing 
mutant D tumor cell killing to wild type IgA and IgG can corroborate our in vitro data and 
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